These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12738448)

  • 1. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
    Suspiro A; Pereira AD; Afonso A; Albuquerque C; Chaves P; Soares J; Leitão CN
    Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic and molecular analysis of high-grade dysplasia and early adenocarcinoma in short- versus long-segment Barrett esophagus.
    Nobukawa B; Abraham SC; Gill J; Heitmiller RF; Wu TT
    Hum Pathol; 2001 Apr; 32(4):447-54. PubMed ID: 11331963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Walch A; Mueller J; Höfler H; Werner M
    J Natl Cancer Inst; 2000 Jul; 92(14):1182-3. PubMed ID: 10904093
    [No Abstract]   [Full Text] [Related]  

  • 7. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
    Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
    J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
    Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
    Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
    Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia.
    Csendes A; Smok G; Quiroz J; Burdiles P; Rojas J; Castro C; Henríquez A
    Am J Gastroenterol; 2002 Mar; 97(3):554-60. PubMed ID: 11922546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal instability in Barrett's esophagus is related to telomere shortening.
    Finley JC; Reid BJ; Odze RD; Sanchez CA; Galipeau P; Li X; Self SG; Gollahon KA; Blount PL; Rabinovitch PS
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1451-7. PubMed ID: 16896031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Morphology and biology of invasion with Barret's carcinoma as an example].
    Werner M; Walch A
    Verh Dtsch Ges Pathol; 2000; 84():62-8. PubMed ID: 11217450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
    Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.